Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqCM - Delayed Quote USD

Petros Pharmaceuticals, Inc. (PTPI)

Compare
0.0691
-0.0169
(-19.65%)
At close: 4:00:01 PM EDT
0.0709
+0.00
+(2.60%)
After hours: 6:13:13 PM EDT

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Fady Boctor M.B.A. President & Chief Commercial Officer 740.46k -- 1978
Mr. Mitchell S. Arnold M.B.A. VP of Finance & Chief Accounting Officer 438.29k -- 1964

Petros Pharmaceuticals, Inc.

1185 Avenue of the Americas
Suite 249
New York, NY 10036
United States
973 242 0005 https://www.petrospharma.com
Sector: 
Healthcare
Full Time Employees: 
21

Description

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

Corporate Governance

Petros Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

March 31, 2025 at 12:00 AM UTC

10-K: Periodic Financial Reports

March 18, 2025 at 12:00 AM UTC

DEF 14A: Proxy Statements

March 14, 2025 at 12:00 AM UTC

PRER14A: Proxy Statements

March 7, 2025 at 12:00 AM UTC

PRE 14A: Proxy Statements

February 21, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

February 14, 2025 at 12:00 AM UTC

CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission

February 13, 2025 at 12:00 AM UTC

CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission

February 11, 2025 at 12:00 AM UTC

CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission

February 10, 2025 at 12:00 AM UTC

S-1/A: Offering Registrations

January 24, 2025 at 12:00 AM UTC

S-1: Offering Registrations

Related Tickers

QNTM Quantum BioPharma Ltd.
7.71
-9.93%
 
RGC Regencell Bioscience Holdings Limited
31.88
+24.19%
 
TLRY Tilray Brands, Inc.
0.6575
-0.78%
 
UPC Universe Pharmaceuticals INC
4.1000
-16.16%
 
CGC Canopy Growth Corporation
0.9100
-7.67%
 
ZYBT Zhengye Biotechnology Holding Limited
5.38
+5.39%
 
ACB Aurora Cannabis Inc.
4.3900
-0.90%
 
TEVA Teva Pharmaceutical Industries Limited
15.37
+1.92%
 
CTOR Citius Oncology, Inc.
0.9300
+39.85%
 
SNOA Sonoma Pharmaceuticals, Inc.
2.1900
-9.13%